<DOC>
	<DOCNO>NCT02341599</DOCNO>
	<brief_summary>The purpose study characterize effect renal function plasma , urine , dialysate pharmacokinetic profile CB-238,618 human . The study also assess safety profile tolerability CB-238,618 subject vary degree renal impairment healthy subject .</brief_summary>
	<brief_title>Study Pharmacokinetics Single IV Dose CB-238,618 Subjects With Varying Degrees Renal Impairment Compared Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Subjects renal impairment mild , moderate , severe renal impairment , ESRD require HD . ESRD subject require HD receive HD three times/week schedule least three month precede initial dose study For healthy subject ( Group A ) : history presence clinically significant illness ( e.g. , cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , musculoskeletal , psychiatric ) condition , include clinically significant anemia , opinion investigator would jeopardize safety subject validity study result For renally impaired subject ( Groups B E ) : , except renal insufficiency medical condition commonly associate renal impairment ( eg , hypertension , diabetes , stable least three month precede initial dose study medication study ) allow Clinically significant abnormality physical examination , medical history , 12lead electrocardiogram ( ECG ) , vital sign , laboratory value , judge investigator designee . Subjects renal impairment clinical laboratory value consistent disease approve investigator Evidence clinically significant hepatic impairment include alanine aminotransferase aspartate aminotransferase &gt; 1.5 × upper limit normal ( ULN ) bilirubin &gt; 1 × ULN Hemoglobin &lt; 8 g/dL , unless consider stable clinically significant opinion investigator subject ESRD HD ; Subjects renal impairment chronic stable drug regimen , define start new drug change dosage within 14 day prior administration study medication , except drug administer relationship HD Subjects fluctuate rapidly deteriorate renal function . Assessment stability subject 's renal function determine investigator Subject currently function renal transplant and/or significant immunosuppressant therapy , determine investigator , within last six month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>